Key Highlights

  • Shares are trading at $34.24, up 6.95% in Friday's session, extending a multi-day rally.
  • The momentum builds on last month's second-quarter Earnings report, which showed an 82% year-over-year Revenue jump and a record 60% gross margin.
  • Several major banks raised price targets on the stock following the Q2 results and a strong showing at a healthcare Investment conference earlier this week.
  • No new company-specific catalyst has been identified today, with the move appearing driven by sustained buying interest and a bullish analyst consensus.

Rally Continues on Sustained Buying Interest

Alamar Biosciences (NASDAQ:ALMR) shares extended their multi-day rally in Friday's session, trading near their 52-week high, as momentum continues to build following last month's standout second-quarter earnings report. Alamar Biosciences is a Fremont, California-based commercial-stage proteomics company that has developed a proprietary Precision Proteomics platform built around its NULISA technology, enabling ultra-sensitive, multiplexed detection and quantification of low-abundance protein biomarkers in biofluids such as blood.

The company's second-quarter results showed an 82% year-over-year revenue jump and a record 60% gross margin, results that continue to reverberate through the stock weeks later.

Analyst Price Target Increases Reinforce the Bullish Case

Investors continue to react to a strong showing at a major healthcare investment conference earlier this week, where shares jumped nearly 9% following management's presentation, and several major banks raised price targets on the stock after the second-quarter results, adding to growing enthusiasm around the company's expanding footprint in multiplexed proteomics.

No Fresh Catalyst Today, Just Continued Conviction

With no new company-specific catalyst identified today, the move appears driven by sustained buying interest amid a bullish analyst consensus rather than any single news event. The company's integrated offering combines its fully automated ARGO HT System instrument, proprietary consumables and assay kits, analytical software, and a technology access program for fee-for-service testing, with more than 100 installed ARGO HT systems and over 300 customers across more than 20 countries following its April 2026 IPO, which raised approximately $191.3 million.